Short- and long-term efficacy of single-dose sub unit vaccines against Yersinia pestis in mice

American Journal of Tropical Medicine and Hygiene

Volumn 58, Issue 6, 1998, Pages 793-799

  Anderson Jr , George W ^a   Heath, David G ^a,b   Bolt, Christopher R ^a   Welkos, Susan L ^a   Friedlander, Arthur M ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Landstuhl Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; EPIDEMIC; IMMUNIZATION; MOUSE; NONHUMAN; PLAGUE; PROTEIN SYNTHESIS REGULATION; YERSINIA PESTIS;

EID: 2642647115     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1998.58.793     Document Type: Article

References (41)

1. Centers for Disease Control, 1994. Human plague - India. MMWR Morb Mortal Wkly Rep 43: 689-691.
2. Centers for Disease Control, 1994. Update: Human plague India. MMWR Morb Mortal Wkly Rep 43: 722-723.
3. Mavalankar DV, 1995. Indian "plague" epidemic: unanswered questions and key lessons. J R Soc Med 88: 547-551.
4. World Health Organization, 1970. WHO expert committee on plague, fourth report. World Health Organ Tech Rep Ser 447: 11-25.
5. Baker EE, Sommer H, Foster LD, Meyer E, Meyer KF, 1952. Studies on immunization against plague. J Immunol 68: 131-145.
6. Lawton VVID, Erdman RL, Surgaila MJ, 1963. Biosynthesis and purification of V and W antigen in Pasteurella pestis. J Immunol 91: 179-184.
7. Simpson WJ, Thomas RE, Schwan TG, 1990. Recombinant capsular antigen (fraction 1) from Yersinia pestis induces a protective antibody response in BALB/c mice. Am J Trop Med Hyg 43: 389-396.
8. Leary SEC, Williamson ED, Griffin KF, Russell P, Eley SM, Titball RW, 1995. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun 63: 2854-2858.
9. Nakajima R, Motin VL, Brubaker RR, 1995. Suppression of cytokines by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun 63: 3021-3029.
10. Friedlander AM, Welkos SL, Worsham PL, Andrews GP, Heath DG, Anderson Jr, GW, Pitt MLM, Estep J, Davis K, 1995. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin Infect Dis 21(suppl 2): S178-S181.
11. Chen TH, Foster LE, Meyer KF, 1961. Experimental comparison of the immunogenicity of antigens in the residue of ultrasonated avirulent Pasteurella pestis with a vaccine prepared with killed virulent whole organisms. J Immunol 87: 64-71.
12. Williamson ED, Eley SM, Griffin KF, Green M, Russell P, Leary SEC, Oyston PCF, Easterbrook T, Reddin KM, Robinson A, Titball RW, 1995. A new improved subunit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12: 223-230.
13. Meyer KF, Foster LE, 1948. Measurement of protective serum antibodies in human volunteers inoculated with plague prophylactics. Stanford Med Bull 6: 75-79.
14. Meyer KF, Hightower JA, McCrumb FR, 1974. Plague Immunization. VI. Vaccination with the fraction I antigen of Yersinia pestis. J Infect Dis 129 (suppl): S41-S45.
15. Andrews GP, Heath DG, Anderson GW Jr, Welkos SL, Friedlander AM, 1996. Fraction I capsular antigen (F1) purification from Yersinia pestis CO92 and an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 64: 2180-2187.
16. Heath DG, Anderson GW Jr. Welkos, SL, Andrews GR, Friedlander AM, Mauro JM, 1997. A recombinant capsular F1-V antigen fusion protein vaccine protects against experimental bubonic and pneumonic plague. Brown F, Burton D, Doherty P, Mekaianos J, Norrby E, eds. Vaccines 97. Cold Spring Harbor. NY: Cold Spring Harbor Laboratory Press, 197-200.
17. Perry RD, Fetherston JD, 1997. Yersinia pestis - etiologic agent of plague. Clin Microbiol Rev 10: 35-66.
18. Roggenkainp A, Geiger AM, Leitritz L, Kessler A, Heesemann J, 1997. Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect Immun 65: 446-451.
19. Williamson ED, Sharp GJE, Eley SM, Vesey PM, Pepper TC, Titball RW, Alpar HO, 1996. Local and systemic immune response to a miroencapsulated subunit vaccine for plague. Vaccine 14: 1613-1619.
20. Anderson GW Jr, Leary SEC, Williamson ED, Titball RW, Welkos SL, Worsham PL, Friedlander AM. 1996. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1 capsule positive and negative strains of Y. pestis. Infect Immun 64: 4580-4585.
21. National Research Council, Institute of Laboratory Animal Resources. 1986. Guide for the Care and Use of Laboratory Animals. DHHS publication (NIH) 86-23. Bethesda, MD: U.S. Department of Health and Human Services.
22. Ball DJ, Argentieri G, Krause R, Lipinski M, Robison RL, Stoll RE, Visscher GE, 1991. Evaluation of a microchip implant system used for animal identification in rats. Lab Anim Sci 41: 185-186.
23. Heath DG, Anderson GW Jr, Mauro JM, Welkos SL, Andrews GP, Adamovicz J, Friedlander AM, 1998. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine: (in press).
24. Price SF, Leung KY, Barve SS, Straley SC, 1989. Molecular analysis of IcrGVH, the V antigen operon of Yersinia pestis. J Bacteriol 171: 5646-5653.
25. Anderson GW Jr, Worsham PL, Bolt CR, Andrews GP, Welkos SL, Friedlander AM, Burans JP, 1997. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the Fl protein of Yersinia pestis. Am J Trop Med Hyg 56: 471-473.
26. U.S. Department of Health and Human Services, 1993. Biosafety in Microbiological and Biomedical Laboratories. Washington DC: USA Government Printing Office.
27. Welkos SL, Davis KM, Pitt LM, Worsham PL, Friedlander AM, 1995. Studies on the contribution of the F1 capsule-associated plasmid pFra to the virulence of Yersinia pestis. Contrib Microbiol Immunol 13: 299-305.
28. Worsham PL, Stein M-P, Welkos SL, 1995. Construction of defined F1 negative mutants of virulent Yersinia pestis. Contrib Microbiol Immunol 13: 325-328.
29. Habig YM, 1993. Potency testing of bacterial vaccines for human use. Vet Microbiol 37: 343-351.
30. Bartelloni PJ, Marshall JD Jr, Cavanaugh DC, 1973. Clinical and serological responses to Plague Vaccine U.S.P. Mil Med 183: 720-722.
31. Meyer KF, Cavanaugh DC, Bartelloni PJ, Marshall Jr JD, 1974. Plague immunization. I. Past and present trends. J Infect Dis 129 (suppl): S13-S18.
32. Burrows TW, 1957. Virulence of Pasteurella pestis. Nature 179: 1246-1247.
33. Marshall Jr JD, Cavanaugh DC, Bartelloni PJ, Meyer KF, 1974. Plague immunization. III. Serologic response to multiple inoculations of vaccine. J Infect Dis 129 (suppl): S26-S29.
34. Newman MJ, Powell MF, 1995. Immunological and formulation design considerations for subunit vaccines. Powell MF, Newman MJ, eds. Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, 1-28.
35. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE, 1995. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 171 (suppl 1): S44-S49.
36. Wiens BL, Bohidar NR, Pigeon JG, Egan J, Hurni W, Brown L, Kuter BJ, Nalin DR, 1996. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 49: 235-241.
37. Centers Disease Control, 1982. Plague vaccine. MMWR Morb Mortal Wkly Rep 31: 301-304.
38. Williams JE, Cavanaugh DC, 1979. Measuring the efficacy of vaccination in affording protection against plague. Bull World Health Organ 57: 309-313.
39. Une T, Brubaker RR, 1984. Roles of V antigen in promoting virulence and immunity in Yersinia. J Immunol 133: 2226-2230.
40. Sato K, Nakajima R, Hara F, Une T, Osada Y, 1991. Preparation of monoclonal antibody to V antigen from Yersinia pestis, Contrib Microbiol Immunol 12: 225-229.
41. Motin VL, Makajima R, Smirnov GB, Brubaker RR, 1994. Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V fusion peptide. Infect Immun 62: 4192-4201.